SUPN – Supernus Pharmaceuticals Inc
SUPN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.82
Margin Of Safety %
16
Put/Call OI Ratio
0.99
EPS Next Q Diff
-0.49
EPS Last/This Y
4.37
EPS This/Next Y
0.31
Price
29.72
Target Price
45.67
Analyst Recom
1.33
Performance Q
-1.99
Upside
325.1%
Beta
-0.58
Ticker: SUPN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-15 | SUPN | 39.56 | 4.28 | 1.00 | 1839 |
| 2026-10-16 | SUPN | 37.87 | 4.32 | 1.52 | 1841 |
| 2026-10-19 | SUPN | 39.81 | 3.85 | 0.00 | 1772 |
| 2026-10-20 | SUPN | 41.15 | 3.83 | 999.99 | 1773 |
| 2026-10-21 | SUPN | 41.2 | 3.84 | 0.40 | 1775 |
| 2026-10-22 | SUPN | 42.08 | 3.84 | 0.40 | 1775 |
| 2026-10-23 | SUPN | 40.66 | 3.85 | 0.00 | 1775 |
| 2026-10-26 | SUPN | 40.78 | 3.85 | 0.00 | 1775 |
| 2026-10-27 | SUPN | 40.93 | 3.85 | 1.00 | 1775 |
| 2026-10-28 | SUPN | 41.15 | 3.85 | 0.50 | 1775 |
| 2026-10-29 | SUPN | 41.84 | 3.85 | 0.50 | 1775 |
| 2026-10-30 | SUPN | 41.94 | 3.84 | 0.00 | 1763 |
| 2026-11-02 | SUPN | 41.92 | 3.84 | 11.00 | 1763 |
| 2026-11-03 | SUPN | 28.15 | 3.77 | 0.20 | 1745 |
| 2026-11-04 | SUPN | 28.27 | 1.08 | 0.06 | 22565 |
| 2026-11-05 | SUPN | 26.76 | 1.04 | 14.00 | 23068 |
| 2026-11-06 | SUPN | 26.18 | 1.06 | 1.19 | 22911 |
| 2026-11-09 | SUPN | 27.62 | 1.06 | 0.19 | 22877 |
| 2026-11-10 | SUPN | 28.77 | 1.06 | 0.01 | 22898 |
| 2026-11-11 | SUPN | 29.45 | 1.00 | 0.16 | 23621 |
| 2026-11-12 | SUPN | 29.21 | 0.99 | 0.14 | 23693 |
| 2026-11-13 | SUPN | 29.72 | 0.99 | 0.04 | 23679 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-15 | SUPN | 39.55 | 1.2 | - | 2.56 |
| 2026-10-16 | SUPN | 37.85 | 1.2 | - | 2.56 |
| 2026-10-19 | SUPN | 39.78 | 1.2 | - | 2.56 |
| 2026-10-20 | SUPN | 39.78 | 1.2 | - | 2.56 |
| 2026-10-21 | SUPN | 41.22 | -8.7 | - | 2.54 |
| 2026-10-22 | SUPN | 42.08 | -8.7 | - | 2.54 |
| 2026-10-23 | SUPN | 40.67 | -8.7 | - | 2.54 |
| 2026-10-26 | SUPN | 40.78 | -19.4 | - | 2.38 |
| 2026-10-27 | SUPN | 40.93 | -19.4 | - | 2.38 |
| 2026-10-28 | SUPN | 41.15 | -19.4 | - | 2.38 |
| 2026-10-29 | SUPN | 41.85 | -19.4 | - | 2.38 |
| 2026-10-30 | SUPN | 41.95 | -19.4 | - | 2.38 |
| 2026-11-02 | SUPN | 41.94 | -19.4 | - | 2.38 |
| 2026-11-03 | SUPN | 28.19 | 17.3 | - | 2.77 |
| 2026-11-04 | SUPN | 28.27 | 17.3 | - | 2.77 |
| 2026-11-05 | SUPN | 26.77 | 17.3 | - | 2.77 |
| 2026-11-06 | SUPN | 26.17 | 48.8 | - | 4.42 |
| 2026-11-09 | SUPN | 27.63 | 48.8 | - | 4.42 |
| 2026-11-10 | SUPN | 28.75 | 48.8 | - | 3.44 |
| 2026-11-11 | SUPN | 29.42 | 48.8 | - | 3.44 |
| 2026-11-12 | SUPN | 29.20 | 25.6 | - | 3.69 |
| 2026-11-13 | SUPN | 29.72 | 25.6 | - | 3.69 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-15 | SUPN | 0.00 | 1.52 | 9.14 |
| 2026-10-16 | SUPN | 0.00 | 1.52 | 9.14 |
| 2026-10-19 | SUPN | 0.00 | 1.45 | 9.14 |
| 2026-10-20 | SUPN | 0.00 | 1.45 | 9.14 |
| 2026-10-21 | SUPN | 0.00 | 1.45 | 9.14 |
| 2026-10-22 | SUPN | 0.00 | 1.45 | 9.14 |
| 2026-10-23 | SUPN | 0.00 | 1.45 | 9.14 |
| 2026-10-26 | SUPN | 0.00 | 2.16 | 9.14 |
| 2026-10-27 | SUPN | 0.00 | 2.16 | 7.42 |
| 2026-10-28 | SUPN | 0.00 | 2.16 | 7.42 |
| 2026-10-29 | SUPN | 0.00 | 2.16 | 7.42 |
| 2026-10-30 | SUPN | 0.00 | 2.16 | 7.42 |
| 2026-11-02 | SUPN | 0.00 | 2.29 | 7.41 |
| 2026-11-03 | SUPN | 0.00 | 2.29 | 3.34 |
| 2026-11-05 | SUPN | 0.00 | 2.29 | 3.34 |
| 2026-11-06 | SUPN | 0.00 | 2.29 | 3.34 |
| 2026-11-09 | SUPN | 0.00 | -4.51 | 3.34 |
| 2026-11-10 | SUPN | 0.00 | -4.51 | 3.34 |
| 2026-11-11 | SUPN | 0.00 | -4.51 | 3.82 |
| 2026-11-12 | SUPN | 0.00 | -4.51 | 3.82 |
| 2026-11-13 | SUPN | 0.00 | -4.51 | 3.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.32
Avg. EPS Est. Current Quarter
1.03
Avg. EPS Est. Next Quarter
0.83
Insider Transactions
Institutional Transactions
-4.51
Beta
-0.58
Average Sales Estimate Current Quarter
371
Average Sales Estimate Next Quarter
392
Fair Value
34.37
Quality Score
65
Growth Score
79
Sentiment Score
43
Actual DrawDown %
50.2
Max Drawdown 5-Year %
-54.1
Target Price
45.67
P/E
8.23
Forward P/E
7.65
PEG
0.37
P/S
4.49
P/B
P/Free Cash Flow
237.81
EPS
3.61
Average EPS Est. Cur. Y
3.69
EPS Next Y. (Est.)
4
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.75
Relative Volume
0.62
Return on Equity vs Sector %
-30.5
Return on Equity vs Industry %
-10.8
EPS 1 7Days Diff
-0.7
EPS 1 30Days Diff
-0.72
EBIT Estimation
◆
SUPN
Healthcare
$29.72
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
63.6
Range 1M
34.4%
Sup Dist
3.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
23.5%
EPS NY
25.8%
52W%
22.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+201% upside
Upside
+201%
Quality
65
MoS
16%
SUPN — P/E HistoricalDrug Manufacturers - Specialty & Generic
Supernus, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 827
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.
SUPN
Latest News
—
Caricamento notizie per SUPN…
stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today
news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance
stock history SUPN – Supernus Pharmaceuticals Inc invest stock market
stock prices SUPN premarket after hours
ticker SUPN fair value insiders trading